News

Antiobesity medications were linked to significant weight regain at 8 weeks after drug discontinuation compared with control group. HealthDay News — Antiobesity medications (AOMs) yield weight loss ...
HealthDay News — Patients with irritable bowel syndrome (IBS) with self-perceived gluten sensitivity react similarly to wheat, gluten, and sham challenges, according to a study published online July ...
US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. signed off on the recommendation from an expert panel that recommended removing the mercury-based preservative from all influenza ...
HealthDay News — Reusable feminine hygiene products often contain per- and polyfluoroalkyl substances (PFAS), according to a study published online July 22 in Environmental Science & Technology ...
Following publication of advisories, reports of local anesthetic poisoning decreased, but reports of lidocaine poisoning and mortality increased.
SAP-001 is an investigational oral agent designed to reduce serum uric acid levels by targeting a distinct renal urate reabsorption transporter.
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3b AVA-PED-301 trial.
Researchers say findings point to gaps in prenatal HIV detection; the majority of infants not treated for HIV infection after birth were Black.
The single-arm, open-label DR-OVP-002 study is currently evaluating Ovaprene in sexually active women aged 18 to 40 years who ...
No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users.
The recall of more than 160,000 bottles of levothyroxine sodium, which went into effect June 20, was upgraded to a Class II recall on July 23. Class II recalls occur when use of the drug poses a ...
Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.